Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on acquisition of the Frösunda Group
Mandate

Vinge advises on acquisition of the Frösunda Group

May 03, 2010

Vinge has advised HgCapital in connection with the acquisition of Frösunda LLS AB and its subsidiaries from Polaris Private Equity Fund II and certain minority shareholders. HgCapital’s team was led by Carl Harring.

The transaction is subject to competition law clearance.

The Frösunda Group is the leading private sector personal care provider to people with functional impairments in Sweden with operations in approximately 40 cities and the group has approximately 3700 employees.

Vinge’s team was led by Malin Leffler (responsible partner) and Martin Hall (project manager) and included associates Jonas Bergström, Johan Cederblad, Daniel Unger, Åsa Gotthardsson, Mårten Svensson and Adam Weissbach. Partner Mikael Ståhl was responsible for acquisition financing, assisted by associates Louise Brorsson Salomon and Sofia Graflund. Peter Alstergren provided competition law advice.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

 Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026